Bicycle Therapeutics (BCYC) Other Non-Current Assets (2018 - 2026)
Bicycle Therapeutics posted quarterly Other Non-Current Assets of $13.0 million for Q1 2026, up 5.11% year-on-year from $12.4 million in Q1 2025, and up 1.46% on a QoQ basis from $12.8 million in Q4 2025.
Bicycle Therapeutics (BCYC) has 9 years of Other Non-Current Assets data on file, last reported at $13.0 million in Q1 2026.
- For the quarter ending Q1 2026, Other Non-Current Assets rose 5.11% year-over-year to $13.0 million; the trailing twelve-month figure through Mar 2026 stood at $13.0 million (up 5.11% YoY), and the FY2025 full-year result was $12.8 million, up 15.63% from the prior year.
- Other Non-Current Assets for Q1 2026 stood at $13.0 million, up from $12.8 million in the prior quarter.
- Across five years, Other Non-Current Assets topped out at $13.8 million in Q2 2025 and bottomed at $4.2 million in Q1 2022.
- The 5-year median for Other Non-Current Assets is $9.9 million (2024), against an average of $9.3 million.
- The widest annual swing landed in 2023, when Other Non-Current Assets jumped 151.69%; it then tumbled 45.83% in 2024.
- A 5-year view of Other Non-Current Assets shows it stood at $8.5 million in 2022, then slumped by 31.52% to $5.8 million in 2023, then surged by 91.19% to $11.1 million in 2024, then rose by 15.63% to $12.8 million in 2025, then rose by 1.46% to $13.0 million in 2026.
- The last three Other Non-Current Assets figures came in at $13.0 million (Q1 2026), $12.8 million (Q4 2025), and $13.7 million (Q3 2025), per Business Quant data.
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Other Non-Current Assets (Qtr) |
|---|---|---|---|---|---|
| 1 | Quantum Biopharma | 1,216,509.61 Bn | 1,216,509.61 Bn | - | - |
| 2 | Alterity Therapeutics | 764,224.41 Bn | 764,224.38 Bn | - | - |
| 3 | Legend Biotech | 2,716.00 Bn | 2,715.71 Bn | 242.10 Mn | 12.40 Mn |
| 4 | Nanobiotix | 2,248.83 Bn | 2,248.77 Bn | - | - |
| 5 | Akari Therapeutics | 1,951.18 Bn | 1,951.17 Bn | - | 60,000.00 |
| 6 | Vertex Pharmaceuticals | 113.69 Bn | 106.44 Bn | 2.59 Bn | 1.26 Bn |
| 7 | Evaxion A | 64.16 Bn | 64.14 Bn | - | - |
| 8 | Regeneron Pharmaceuticals | 63.94 Bn | 55.18 Bn | 3.31 Bn | 2.13 Bn |
| 9 | Alnylam Pharmaceuticals | 40.13 Bn | 37.12 Bn | 959.66 Mn | 63.55 Mn |
| 10 | Bicycle Therapeutics | 326.82 Mn | 326.82 Mn | - | 12.99 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 12.99 Mn |
| Dec 31, 2025 | 12.81 Mn |
| Sep 30, 2025 | 13.71 Mn |
| Jun 30, 2025 | 13.81 Mn |
| Mar 31, 2025 | 12.36 Mn |
| Dec 31, 2024 | 11.07 Mn |
| Sep 30, 2024 | 9.94 Mn |
| Jun 30, 2024 | 6.58 Mn |
| Mar 31, 2024 | 6.37 Mn |
| Dec 31, 2023 | 5.79 Mn |
| Sep 30, 2023 | 5.45 Mn |
| Jun 30, 2023 | 12.15 Mn |
| Mar 31, 2023 | 10.57 Mn |
| Dec 31, 2022 | 8.46 Mn |
| Sep 30, 2022 | 6.16 Mn |
| Jun 30, 2022 | 5.10 Mn |
| Mar 31, 2022 | 4.20 Mn |
| Dec 31, 2021 | 3.45 Mn |
| Sep 30, 2021 | 2.78 Mn |
| Jun 30, 2021 | 2.38 Mn |
| Mar 31, 2021 | 2.18 Mn |
| Dec 31, 2020 | 1.82 Mn |
| Sep 30, 2020 | 2.40 Mn |
| Jun 30, 2020 | 2.27 Mn |
| Mar 31, 2020 | 1.87 Mn |
| Dec 31, 2019 | 1.70 Mn |
| Sep 30, 2019 | 1.48 Mn |
| Jun 30, 2019 | 1.41 Mn |
| Dec 31, 2018 | 3.04 Mn |